All the Active Ingredient Drugs
IgG1 kappa immunoglobulin. amivantamab 50 mg/ml. Vial, conc. for sol. for inf. 1 vial 350 mg/ 7 ml
Administer via peripheral line for Week 1 Day 1 and 2 and Week 2 to reduce the risk of infus. related reactions.
When administering in combin. with carboplatin and pemetrexed, infuse pemetrexed first, carboplatin second, and amivantamab last.
When administering in combin. with lazertinib, administer lazertinib orally any time before the amivantamab infus.
When administering in combin. with lazertinib, administer anticoagulant prophylaxis to prevent venous thromboembolic (VTE) events for the first 4 mo of tmt. See prescrib. info
First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substit. Mutat.
First-line tmt. of adults with locally adv. or metast. non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substit. mutat., as detected by an approved test, in combin. with Lazertinib.
Previously Treated NSCLC with EGFR Exon 20 Insertion Mutat.
Tmt of adults with locally adv. or metast. non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutat., as detected by an approved test, whose dis. has progress. on or after platinum-based chemother.
First line tmt. of NSCLC with EGFR Exon 20 Insertion Mutat.
First-line tmt of adults with locally adv. (not amenable to curative ther.) or metast. NSCLC with activating EGFR Exon 20 insertion mutat. in combin. with carboplatin and pemetrexed.
Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substit. Mutat.
Tmt. of adults with locally adv. or metast. non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substit. mutat., whose dis. has progressed on or after tmt. with an EGFR tyrosine kinase inhibitor (TKI), in combin. with carboplatin and pemetrexed.
C/I: Hypersens.
